PR Newswire BiotechOriginal article
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
Positive
AI Analysis
Summary
IASO Biotechnology completed its acquisition of Singapore-based cell therapy company MediSix Therapeutics, expanding its immune cell engineering and cell therapy capabilities.
Outcome Details
Acquisition completed
Importance:6/10
Sentiment:
0.50
acquisitioncell_therapyimmune_cell_engineeringSingaporeChina
Related Companies
Read the original article
Published by PR Newswire Biotech on August 13, 2026 11:06 AM